PTGX - Protagonist Therapeutics, Inc.
| Previous Close | 7.16 |
| Open | 7.22 |
| Bid | 7.30 x 1800 |
| Ask | 7.77 x 1800 |
| Day's Range | 7.11 - 7.46 |
| 52 Week Range | 4.47 - 16.67 |
| Volume | 223,650 |
| Avg. Volume | 678,770 |
| Market Cap | 198.607M |
| Beta (5Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.94 |
| Earnings Date | Mar 09, 2020 - Mar 15, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.17 |
- Zacks
Protagonist (PTGX) Starts Study on PTG-300 for Blood Disorder
Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.
- PR Newswire
Protagonist Therapeutics Achieves Milestone in Janssen Biotech, Inc., Collaboration
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced the achievement of a research milestone under its worldwide license and research collaboration agreement with Janssen Biotech, Inc. ("Janssen"), for co-development activities with affiliate Janssen Research & Development, LLC, and commercialization of oral, gut-restricted IL-23 receptor antagonist PTG-200 (JNJ-67864238) and second generation peptides for all indications including inflammatory bowel disease (IBD). The successful nomination of a second-generation development candidate triggers a $5 million milestone payment to Protagonist.
- PR Newswire
Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that a Phase 2 study of its novel hepcidin mimetic PTG-300 in patients with hereditary hemochromatosis has been initiated. Hereditary hemochromatosis is a blood disorder that causes the body to absorb too much iron from the diet, resulting in the accumulation of iron in the body's tissues and organs, particularly in skin, heart, liver, pancreas and joint tissues.
- Insider Monkey
Here is What Hedge Funds Think About Protagonist Therapeutics, Inc. (PTGX)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- Simply Wall St.
Insider Buying: The Protagonist Therapeutics, Inc. (NASDAQ:PTGX) CEO, President Just Bought US$169k Worth Of Shares
Investors who take an interest in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) should definitely note that the CEO...
- Benzinga
The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 3) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares ...
- PR Newswire
Protagonist Therapeutics Announces Preliminary Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Transfusion Dependent Beta-Thalassemia
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced preliminary results from patients with transfusion-dependent (TD) beta-thalassemia in the ongoing TRANSCEND Phase 2 open-label study of PTG-300. Dose-related drug exposure and reductions from baseline serum iron and transferrin saturation (TSAT) levels were observed, with significant reductions at the 40 mg and 80 mg weekly doses (p < 0.02 for each assessment, see graphs below).
- PR Newswire
Protagonist Therapeutics to Present at Two Upcoming Healthcare Investor Conferences
NEWARK, Calif. , Nov. 13, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will present at two upcoming ...
- Zacks
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 18.67% and -27.98%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Protagonist Therapeutics Reports Third Quarter 2019 Financial Results
-- Preliminary Phase 2 results for hepcidin mimetic PTG-300 in beta-thalassemia are expected in the fourth quarter of 2019 -- -- Company sponsored Phase 2 study of PTG-300 in hereditary hemochromatosis ...
- PR Newswire
Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease
NEWARK, Calif., Nov. 6, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced that the first patient has been dosed in a Phase 2 study of PTG-200 (also referenced as JNJ-67864238) in patients with moderate to severe Crohn's disease. PTG-200 is an oral, gut-restricted, interleukin-23 receptor (IL-23R) antagonist for the potential treatment of inflammatory bowel diseases. Protagonist Therapeutics and Janssen Research & Development are jointly conducting the development of PTG-200 through completion of Phase 2 clinical proof of concept in the treatment of Crohn's disease.
- PR Newswire
Protagonist Therapeutics Secures Debt Facility for up to $50 Million
NEWARK, Calif., Oct. 31, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today announced it has entered into a four-year debt facility with MidCap Financial (MidCap), the lead agent, and Silicon Valley Bank (SVB). The lenders under the debt facility will make available to Protagonist an aggregate principal amount up to $50 million. $10 million of the facility has been funded at closing, with the ability to access the remaining $40 million, subject to the achievement of certain clinical development milestones and other specified conditions.
- Zacks
Earnings Preview: Protagonist Therapeutics (PTGX) Q3 Earnings Expected to Decline
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Benzinga
The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 21.) Aprea Therapeutics Inc (NASDAQ: APRE ) AVITA ...
- Benzinga
The Week Ahead In Biotech: Earnings Trickle In, While Glaxo, Melinta, Foamix And Eton Await FDA Verdict
Biotech stocks saw some strength last week. Positive clinical readouts, a couple of M&A deals and hopes of drug companies clinching a broader opioid settlement agreement worked in favor of the sector. ...
- Simply Wall St.
The Protagonist Therapeutics (NASDAQ:PTGX) Share Price Is Down 45% So Some Shareholders Are Getting Worried
For many investors, the main point of stock picking is to generate higher returns than the overall market. But the...
- PR Newswire
Protagonist Therapeutics Announces Acceptance of Abstracts at the UEG Week 2019 Meeting and the ACG 2019 Annual Scientific Meeting
NEWARK, Calif. , Oct. 1, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that abstracts providing data from the PN-943 and PTG-200 clinical programs have been accepted ...
- PR Newswire
Protagonist Therapeutics to Present at the Cantor Global Healthcare Conference on Wednesday, October 2
NEWARK, Calif. , Sept. 25, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will present at the Cantor ...
- PR Newswire
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, Calif., Sept. 4, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (PTGX) today reported that on August 30, 2019, it issued inducement awards to two recently hired employees in accordance with their employment offer letters. The awards were granted under the Protagonist Therapeutics Inducement Award Plan, which was adopted May 29, 2018. For Arjun Agarwal, Vice President, Controller, an option to purchase 30,000 shares of common stock.
- PR Newswire
Protagonist Therapeutics to Present at the H.C. Wainwright & Co. 2019 Annual Healthcare Conference
NEWARK, Calif. , Sept. 3, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will provide a corporate ...
- Simply Wall St.
Does Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Salary Reflect Performance?
Dinesh Patel became the CEO of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) in 2008. This analysis aims first to...
- Zacks
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -337.04% and -176.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Protagonist Therapeutics Reports Second Quarter 2019 Financial Results
-- Preliminary Phase 2 results for hepcidin mimetic PTG-300 in beta-thalassemia are expected in the fourth quarter of 2019 -- -- Phase 2 study of PTG-300 in polycythemia vera expected to begin in the third ...
- PR Newswire
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study
-- PN-943 is safe and well tolerated with gut-restricted exposure; Phase 2 ulcerative colitis study initiation planned for early 2020 -- -- Pharmacodynamic data for PN-943 in healthy volunteers confirm ...
- Zacks
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
